Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 5156-5162, November 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nomura, T.
Right arrow Articles by Gotoh, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nomura, T.
Right arrow Articles by Gotoh, H.

Antiteratogenic Effects of Tumor Inhibitors, Caffeine, Antipain, and Retinoic Acid in Mice1

Taisei Nomura2, Takayuki Enomoto3, Keiko Shibata, Tohru Kanzaki4, Hiroyuki Tanaka5, Shinsuke Hata3, Sakae Kimura, Takeshi Kusafuka3, Kazushi Sobue3, Shinpei Miyamoto3, Hiroshi Nakano3 and Hiroko Gotoh

Institute for Cancer Research and Department of Fundamental Radiology, Osaka University Medical School, 1-1-50, Fukushima, Fukushima-ku, Osaka 553, Japan

To learn the effects of tumor inhibitors on chemically induced malformations, caffeine, antipain, and 13-trans-retinoic acid were given to pregnant ICR/Jcl mice after a single dose of urethan, N-hydroxyurethan, N-methyl-N-nitrosourea, N-ethyl-N-nitrosourea, or 4-nitroquinoline 1-oxide, which induces about 50% of the malformed fetuses. When caffeine was given immediately after carcinogen treatment on Day 10, urethan- and N-ethyl-N-nitrosourea-induced malformations were significantly suppressed by caffeine posttreatment, while N-hydroxyurethan- and N-methyl-N-nitrosourea-induced malformations were not suppressed by caffeine. 4-Nitroquinoline 1-oxide-initiated teratogenesis was also suppressed, but not significantly so (p {fallingdotseq} 0.07). The results were very similar to those of the effects of caffeine on tumors induced by these carcinogens. Malformations of genetic origin (cleft palates and cleft lips) in CL/Fr mice were also suppressed significantly by caffeine treatment on Days 8 to 11, although the level of inhibition was less than that in chemically induced malformations. A protease inhibitor (antipromotor), antipain, also suppressed urethan-induced malformations. The antiteratogenic effects of antipain were most effective when it was given during the period of 24 to 48 hr after urethan treatment, while those of caffeine were most effective when it was given immediately after urethan. The promoting process might be involved in chemically induced teratogenesis, as it was in carcinogenesis. A natural retinoid (13-trans-retinoic acid) also suppressed urethan-induced malformations. Thus, tumors and malformations induced by chemical carcinogens were suppressed by tumor inhibitors, suggesting the similarity of both processes in the subcellular level, in spite of their morphological differences.

1 This work was supported by grants from the Japanese Ministry of Education, Science, and Culture and from the Medical Science Promotion Foundation.

2 To whom requests for reprints should be addressed, at Institute for Cancer Research, Osaka University Medical School, 1-1-50, Fukushima, Fukushima-ku, Osaka 553, Japan.

3 Students of Osaka University Medical School.

4 Present address: Department of Obstetrics and Gynecology, Osaka University Medical School, 1-1-50, Fukushima, Fukushima-ku, Osaka 553, Japan.

5 Present address: Department of Pediatrics, Osaka University Medical School, 1-1-50, Tukushima-ku, Osaka 553, Japan.

Received 2/10/83. Accepted 8/ 9/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.